Pleco Therapeutics BV is a Dutch private limited company, established to develop a portfolio of therapies in the field of cancer medicine. Pleco utilises a global network of academic centres and contract research organisations to test highly-efficient Fixed-Dose Combinations, repurposing existing therapies. The first products are currently being tested in preclinical models. Pleco targets diseases with orphan designation to expedite the development process.
The development of our products is based on a novel proprietary platform with a strong IP-position. Pleco pursues an aggressive patent strategy that includes patent applications on manufacturing process and delivery vehicle. This will strengthen and expand our core business and augment the portfolio strength.